Boston Scientific Corporation

Boston Scientific Corporation Earnings Recaps

BSX 4 recaps
Next earnings: February 3, 2027 (estimated) · full calendar
Q3 2026 Oct 30, 2026

Boston Scientific fell 5.8% after a sharp Q3 miss and a weaker outlook: organic sales grew 1.5%, below the company’s 3%–5% guide, and Q4 guidance calls for an organic revenue decline of 1%–3%. Beyond the cyber incident’s near-term impact, investors face intensifying EP competition, pressure on WATCHMAN, and management’s warning that 2027 sales and adjusted EPS could be difficult to grow.

Key takeaways
  • Q3 adjusted EPS was $0.73, versus company guidance of $0.80–$0.82; management estimated the cyber incident reduced sales growth by about 300 basis points and adjusted EPS by $0.07.
  • For Q4, the company expects organic revenue to decline 1%–3% and adjusted EPS of $0.77–$0.79, citing cyber-related effects, inventory replenishment after elevated customer orders, EP share pressure, and tougher China pricing.
  • Full-year 2026 guidance is 4% organic revenue growth and adjusted EPS of $3.16–$3.18. Management expects 2027 to be a trough year and says sales and adjusted EPS may be challenging to grow, excluding Penumbra.
  • Performance was uneven: neuromodulation sales grew 13%, while urology declined 3%; U.S. operational sales were flat and Asia Pacific declined 1%.
  • Management expects new launches and restructuring actions to support stabilization and a return to growth in 2028, but that recovery is prospective rather than a near-term offset to the outlook.
Q2 2026 Aug 1, 2026

Boston Scientific's shares were essentially unchanged (-0.1%) as the quarter showed steady organic sales growth and solid margins, but the market digested cautious guidance revisions driven by softness in WATCHMAN and electrophysiology (EP) segments.

Key takeaways
  • Q2 organic revenue grew 7%, driven by Interventional Cardiology, Endoscopy, and Neuromodulation, within prior full-year guidance range.
  • Adjusted EPS of $0.86 rose 15%, aided by favorable tax outcomes, and operating margin was healthy at 28.4%.
  • Guidance trimmed: full-year organic growth now expected at 5%-6%, below previous midpoint; adjusted EPS growth moderation reflected in narrowed $3.28-$3.32 range.
  • Key headwinds in WATCHMAN (clinical evidence impacting referrals) and EP (unexpected share loss in U.S.) pressured outlook; these segments weigh on near-term growth.
  • Restructuring plan announced to deliver $500 million in run-rate savings by 2029, aiming to offset pressures and underpin improved growth in 2028 and beyond.
Q1 2026 Apr 22, 2026

Boston Scientific delivered a solid Q1 with 9.4% organic sales growth and adjusted EPS at the high end of guidance, though the company has lowered its full-year outlook due to unexpected headwinds affecting growth trajectories.

Key takeaways
  • Q1 organic revenue exceeded guidance at 9.4%, with adjusted EPS of $0.80, growing 6%.
  • Full-year 2026 organic growth guidance reduced to 6.5–8% from prior expectations, reflecting unanticipated challenges.
  • U.S. region showed robust 11% growth, driven by multiple business units; EMEA and Asia Pacific experienced slower and strong growth respectively.
  • Growth in segments like Neuromodulation remained strong at 15%, while Urology faced challenges with only 1% growth amid product gaps and market disruptions.
  • The company remains committed to strategic investments and innovation, despite near-term headwinds impacting some product categories and regional markets.
Q3 2025 Oct 23, 2025

Boston Scientific's Q3 2025 results surpassed expectations with 19% operational sales growth and a 15% increase in organic sales, driven by strong performances in Cardiovascular and MedSurg segments.

Key takeaways
  • Adjusted EPS rose 19% to $0.75, exceeding guidance and signaling robust operational efficiency.
  • U.S. operations experienced exceptional growth at 27%, while the Asia-Pacific region also performed strongly with a 17% increase.
  • Although EMEA saw a 2% decline due to temporary headwinds, underlying growth was strong, indicating resilience in key markets.
  • Full-year adjusted EPS guidance raised to $3.02 to $3.04, reflecting the company's confidence in continued above-market growth.
  • Upcoming acquisition of Nalu Medical poised to enhance Boston Scientific's portfolio in the interventional pain market, expected to close in H1 2026.